K. Hawkins

发表

Thalidomide Maintenance Following High Dose Therapy in Multiple Myeloma: A UK Myeloma Forum Phase 2 Study.

J. Snowden, A. Rawstron, S. Feyler, 2005 .

A randomised study of whole-breast vs tumour-bed irradiation after local excision and axillary dissection for early breast cancer.

D. Ash, D. Dodwell, D. Dodwell, 2005, Clinical oncology (Royal College of Radiologists (Great Britain)).

A randomized phase II study of BB‐10010: a variant of human macrophage inflammatory protein‐1α for patients receiving high‐dose etoposide and cyclophosphamide for malignant lymphoma and breast cancer

J. Fay, C. Eaves, D. Reece, 1997 .

Minimization—reducing predictability for multi‐centre trials whilst retaining balance within centre

Julia Brown, Sarah Brown, Helen Thorpe, 2005, Statistics in medicine.

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.

G. Morgan, M. Drayson, F. Davies, 2003, The New England journal of medicine.

Inhibition of tumour growth by marimastat in a human xenograft model of gastric cancer: relationship with levels of circulating CEA

T. Morris, L. Bawden, E. Bone, 1999, British Journal of Cancer.

Agreement between preoperative core needle biopsy and postoperative invasive breast cancer histopathology is not dependent on the amount of clinical material obtained

A. Hanby, K. Hawkins, J. Beazley, 2004, Journal of Clinical Pathology.

BAX UTR G (-248) A Polymorphism Has No Impact on Survival in Patients with Multiple Myeloma.

G. Morgan, C. Fegan, F. Davies, 2006 .

A randomized phase II study of BB-10010: a variant of human macrophage inflammatory protein-1alpha for patients receiving high-dose etoposide and cyclophosphamide for malignant lymphoma and breast cancer.

J. Fay, C. Eaves, D. Reece, 1997, British Journal of Haematology.

Follow up Analysis for MRC Myeloma VII Trial.

G. Morgan, M. Drayson, F. Davies, 2004 .